Long-term omalizumab treatment – do drug concentration levels count?

J. Kroes (Leeuwarden, Netherlands), S. Zielhuis (Leeuwarden, Netherlands), A. Van Der Meer (Leeuwarden, Netherlands), K. De Jong (Leeuwarden, Netherlands), E. Van Roon (Leeuwarden, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands)

Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases
Session: Personalised treatment of obstructive diseases
Session type: E-poster session
Number: 2676
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Kroes (Leeuwarden, Netherlands), S. Zielhuis (Leeuwarden, Netherlands), A. Van Der Meer (Leeuwarden, Netherlands), K. De Jong (Leeuwarden, Netherlands), E. Van Roon (Leeuwarden, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands). Long-term omalizumab treatment – do drug concentration levels count?. 2676

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Immunomodulatory treatment of severe persistent asthma with interferon-αcon-1 (IFN-αcon-1). Effect on the clinical course of oral corticosteroid dose and eosinophil numbers
Source: Annual Congress 2003 - Modulation of bronchial hyperreactivity and immune response in the airways
Year: 2003

Oral corticosteroid treatment reduces serum chitotriosidase activity in patients with COPD
Source: Annual Congress 2010 - COPD: treatment and monitoring
Year: 2010

Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019

A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial
Source: Eur Respir J, 58 (3) 2004522; 10.1183/13993003.04522-2020
Year: 2021

Analysis of IMPACT: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD?
Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights
Year: 2019

Quantitative IgE levels in asthma and implications for treatment with omalizumab. Are the cutoffs to narrow?
Source: Annual Congress 2011 - Asthma management and response
Year: 2011

Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD
Source: Eur Respir J, 55 (5) 1902119; 10.1183/13993003.02119-2019
Year: 2020

Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIR says no!
Source: Eur Respir J, 51 (5) 1800730; 10.1183/13993003.00730-2018
Year: 2018

Association between blood eosinophil count and exacerbation risk in patients with asthma receiving medium- or high-dosage inhaled corticosteroids
Source: International Congress 2017 – Biomarker-based asthma control
Year: 2017

Changes in eosinophil count and C reactive protein following treatment with mebendazole in patients with Toxocara-associated asthma
Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections
Year: 2010

The efficacy of omalizumab in severe in asthma after treatment withdrawal
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009

Relationship between pre-treatment specific IgE and the response to omalizumab therapy
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008

Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011

Long-term bortezomib treatment decreases allergen-specific IgE but fails to amend chronic asthma in mice
Source: Annual Congress 2012 - Asthma: mechanisms of airway inflammation
Year: 2012

Add on therapy of pure theophylline sollution with systemic corticosteroid is more effective for the treatment of asthma attack
Source: Eur Respir J 2004; 24: Suppl. 48, 344s
Year: 2004

Does combination therapy lead to better adherence in asthma?
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Long-term oral corticosteroid-sparing effects of anti-IL5/anti-IL5 receptor treatment.
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021

Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008

Case series of long-term macrolide therapy effect on eosinophil count in COPD
Source: International Congress 2017 – COPD management
Year: 2017

Stability and achievement of asthma control with higher doses of inhaled conticosteroids regular treatment
Source: Annual Congress 2011 - Asthma management and response
Year: 2011